Publication | Closed Access

CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial

Hematological MalignancyOncologyCpx-351 Versus 7+3Mixed-phenotype Acute LeukemiaHematologyClinical TrialsMyeloid NeoplasiaPharmacotherapyOlder AdultsMedicineRadiation OncologyCancer ResearchPhase 3Health Sciences